At ArcVance, our mission is to transform liquid biopsy into a faster, more accurate, and more accessible diagnostic tool for clinicians and researchers worldwide. We address the critical need to preserve the integrity of blood-based biomarkers, cell-free DNA, RNA, extracellular vesicles, proteins, and metabolites, that are often degraded before analysis. Leveraging our patented microfluidic plasma isolation technology, ExoArc®, we deliver ultra-pure plasma at the point of care, eliminating cellular noise and enabling earlier, more reliable disease detection.

We are dedicated to empowering the medical community with innovative, user-friendly solutions that fit seamlessly into clinical and research workflows. Our goal is to accelerate the adoption of next-generation diagnostics, improve patient outcomes, and reduce healthcare costs. Guided by scientific excellence and a passion for impact, ArcVance is committed to making high-quality biomarker analysis a standard in precision medicine for cancer and beyond.